Skip to main content

Table 4 Randomized trials of low molecular weight heparin (LMWH) in unstable angina and non-Q-wave myocardial infarction (MI)

From: Arterial indications for the low molecular weight heparins

     Treatment     
     duration Follow-up LMWH Control  
Study LMWH n Primary outcome (days) (days) (%) (%) P
Gurfinkel et al, n 211 MI, death, recurrent angina, urgent 5–7 5–7 22 59* 0.00001
1995 [19]    revascularization, major bleeding     63 0.00001
FRISC, 1996 [20] Dalteparin 1506 MI – death 35–45 6 1.8 4.8 0.001
      40 8.0 10.7 0.07
      150 14 15.5 0.41
FRIC, 1997 [23] Dalteparin 1506 MI/death/recurrent angina 6 6 9.3 7.6 0.33
     45 6–45 12.3 12.3 0.96
ESSENCE, 1997 [24] Enoxaparin 3171 MI/death/recurrent angina 2–8 14 16.6 19.8 0.02
      30 19.8 23.3 0.02
       6/14 days   
FRAXIS, 1999 [28] Nadroparin 3468 MI/death/refractory angina 6 or 14 6 13.8/15.8 14.9 ns
      14 17.8/20.0 18.1 ns
      90 22.3/25.2 22.2 ns
FRISC II, 1999 [26] Dalteparin 2267 Death – MI 90 30 3.1 5.9 0.002
      90 6.7 8.0 0.17
TIMI 11b, 1999 [27] Enoxaparin 3910 Death/MI/urgent revascularization 8 or 43 14 14.2 16.6 0.03
      43 17.3 19.6 0.049
  1. ns, Not significant. * Aspirin, heparin, placebo.
\